Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company's board of directors, effective July 1, 2022. Ms. Liu will serve as an independent director and as a member of the Nominating & Corporate Governance Committee.

"I'm thrilled to welcome Vivian to Aytu's board of directors as we continue to transform the company and focus on our key growth drivers of growing our commercial businesses and building a valuable therapeutics pipeline focused on complex and pediatric-onset rare diseases, said Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "Vivian's broad skill set and deep expertise across clinical and corporate development, along with her significant experience in building and leading emerging biotechnology companies, will serve the company very well. Her global business development knowledge will help us scale as we aim to deliver long-term value to shareholders. I sincerely appreciate Vivian joining our board at this important time in the company's history."

Vivian Liu commented, "I am excited to be joining Aytu's board of directors and look forward to assisting the management team as the company continues to make progress on its strategic plans. As an executive and entrepreneur operating for many years in biotech and pharmaceuticals, I can appreciate the challenges and opportunities that lie ahead and am ready to help lead Aytu as the company continues to grow."

Vivian Liu currently serves as Head of Corporate Affairs for PREMIA Holdings (HK) Limited, a developer of clinical-genomic oncology databases and service provider to pharmaceutical companies seeking to operate clinical trials throughout Asia. Prior to joining PREMIA, Vivian served in various roles, including as a member of Board of Directors and President, Chief Executive Officer and Chief Financial Officer for Innovus Pharmaceuticals, Inc., a publicly listed consumer healthcare company acquired by Aytu BioPharma in February 2020. Prior to Innovus, she served as the President and Chief Executive Officer of FasTrack Pharmaceuticals, Inc.